Scleroderma Queensland
  • Home
  • About Us
    • Your Committee
    • Members' Stories
  • Become a Member
    • Printable Membership Form
    • Online Membership Form
  • Donations
  • RESEARCH
  • FUNDRAISING
  • News
  • EVENTS
  • Group Meetings
  • GET SUPPORT
  • RESOURCES
  • Contact Us
  • Newsletter

Stem cell transplant normalizes scleroderma gene activity: Study

26/7/2024

 
SCOT trial studied potential benefits over high-dose Cytoxan by Andrea Lobo, PhD | July 16, 2024
Picture
Patients with systemic sclerosis (SSc) who have a stem cell transplant see normalized gene activity related to immune function up to 4.5 years after the procedure.

That’s according to recent data from samples in the Phase 2/3 SCOT trial (NCT00114530), wherein the potential benefits of a stem cell transplant were compared with those of high-dose Cytoxan (cyclophosphamide) in severe SSc.
“The normalization of the SSc [molecular] signature … parallels the clinical benefits of [stem cell transplant] at this time point and provides support for these disease-related pathways as therapeutic targets,” the researchers wrote in “Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long-Term Normalization of Systemic Sclerosis Molecular Signatures,” which was published in Arthritis & Rheumatology.

SSc, or scleroderma, is an autoimmune disease where scar tissue (fibrosis) accumulates in the skin and possibly in the organs, such as the lungs, heart, or kidneys.
​
Transplanting hematopoietic stem cells (HSC), which are precursors to all types of blood cells, has been investigated as a way to reset the immune system in people with SSc.
​Comparing stem cell transplant, CytoxanIn
SCOT, 75 adults, ages 18-69, with severe SSc and extensive skin and internal organ involvement, were randomly assigned to an autologous stem cell transplant or to one year of monthly Cytoxan infusions. An autologous transplant involves collecting healthy bone marrow stem cells from a patient, who is then treated with a conditioning regimen to wipe out the rest of their stem cells before the collected ones are reintroduced surgically.

Data from SCOT previously showed stem cell transplants significantly increased patient survival over Cytoxan. After 11 years, the estimated survival was 80% for those who had the transplant and 52% for those on Cytoxan.
​
Before treatment, that is, the baseline, patients had a higher activity of interferon and neutrophil-related genes, and decreased activity of cytotoxic/natural killer (NK)-related genes, compared with healthy people. Interferons are proteins that form part of the body’s natural defenses, while neutrophils are immune cells involved in scarring that release certain molecules to control the immune response. NK cells detect and eliminate infected cells and cancer cells. 

After 26 months, or slightly more than two years, the gene activity changes normalized for those who had the transplant.

Here, two later time points are reported — at 38 months, or more than three years, with data from 19 transplanted and 11 Cytoxan-treated patients, and at 54 months, or 4.5 years, with data from 16 transplanted and 11 Cytoxan-treated participants.

Compared with the baseline, there was lower activity in interferon genes and higher activity of NK-related genes at both time points in the transplant patients, “indicating a long-term normalization of baseline SSc gene expression signature,” the investigators wrote. No such effects were seen with Cytoxan.

After 38 months, the transplant group had more activity of genes related to B-cells, which are immune cells that produce antibodies, and a downregulation of genes related to myeloid cells, which are white blood cells, and inflammation, over healthy participants.

After 54 months, there were no difference in gene activity between the stem cell transplant group and healthy people, suggesting a complete “reconstitution” of the immune system. Those treated with Cytoxan had stable gene activity and continued to have the SSc gene expression signature.
​
“We show [stem cell transplant] can normalize the SSc immune dysregulation on a long-term basis. These findings parallel the observed long-term clinical benefits of this treatment modality,” wrote the researchers, who said the data contribute to evidence that hematopoietic stem cell transplant may be an effective disease-modifying option for severe SSc.

Comments are closed.

    Author

    Scleroderma Queensland Support Group

    Archives

    May 2025
    April 2025
    March 2025
    February 2025
    January 2025
    December 2024
    November 2024
    October 2024
    September 2024
    August 2024
    July 2024
    June 2024
    May 2024
    April 2024
    March 2024
    February 2024
    January 2024
    May 2023
    April 2023
    March 2023
    February 2023
    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    February 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    March 2020

    Categories

    All
    Announcements
    Community
    Members Stories
    Research
    Resources
    Scleroderma
    Support
    Support Group Meetings
    Useful Links

Scleroderma ​Association of Queensland
ABN 91 905 099 795

​About Us | Members' Stories | Group Meetings | Become a Member
Donate now
Phone 0468 801 021  Email [email protected]
Postal Address 54 Avocado Lane, Maleny, QLD, 4552
©Scleroderma Association of Queensland. ​All rights reserved. Website by Grey and Grey. 
  • Home
  • About Us
    • Your Committee
    • Members' Stories
  • Become a Member
    • Printable Membership Form
    • Online Membership Form
  • Donations
  • RESEARCH
  • FUNDRAISING
  • News
  • EVENTS
  • Group Meetings
  • GET SUPPORT
  • RESOURCES
  • Contact Us
  • Newsletter